<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03845140</url>
  </required_header>
  <id_info>
    <org_study_id>MS200661_0003</org_study_id>
    <nct_id>NCT03845140</nct_id>
  </id_info>
  <brief_title>L-PZQ ODT in Schistosoma Infected Children</brief_title>
  <official_title>An Open Label, Phase III Efficacy and Safety Study of L-PZQ ODT in Schistosoma Infected Children 3 Months to 6 Years of Age, Including a 2:1 Randomized, Controlled Cohort of Schistosoma Mansoni Infected Children 4 to 6 Years of Age Treated With L PZQ ODT or Commercial PZQ (Biltricide®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the safety and efficacy of L-praziquantel orodispersible (L-PZQ ODT)&#xD;
      tablets in Schistosoma infected children aged 3 months to 6 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2, 2019</start_date>
  <completion_date type="Actual">October 11, 2021</completion_date>
  <primary_completion_date type="Actual">October 11, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numbers of Participants With Clinical Cure</measure>
    <time_frame>17 to 21 days post-treatment</time_frame>
    <description>Clinical cure is defined as no parasite eggs in the stool or urine 17 to 21 days post-treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Egg Reduction Rate</measure>
    <time_frame>Pre-treatment, 17 to 21 days post-treatment</time_frame>
    <description>Egg reduction rate will be calculated using parasite egg counts as determined by the Kato Katz method for Cohorts 1, 2 and 3 and the urine filtration method for Cohort 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cure Rate</measure>
    <time_frame>17 to 21 days post-treatment</time_frame>
    <description>Cure defined as no evidence of parasite antigens in urine as measured with Point-of-Care Circulating Cathodic Antigen (POC-CCA) test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of the Study Intervention</measure>
    <time_frame>Day 1</time_frame>
    <description>Acceptability of the study intervention will be recorded as the reaction of participants to study intervention. The acceptability will be assessed by the nurse/site staff for all children enrolled in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of L-PZQ ODT</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) of L-PZQ ODT</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of L-PZQ ODT</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and Severity of Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs)</measure>
    <time_frame>Day 1 up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Treatment Related Adverse Events</measure>
    <time_frame>Day 1 up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Vital Signs, Laboratory Parameters and 12-lead Electrocardiogram (ECG) Findings</measure>
    <time_frame>Day 1 up to Day 21</time_frame>
    <description>Number of participants with clinically significant changes will be reported.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">311</enrollment>
  <condition>Schistosomiasis</condition>
  <arm_group>
    <arm_group_label>Cohort 1, Treatment 1a: L-PZQ ODT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 4 to 6 years infected with Schistosoma (S.) mansoni will receive single oral dose of L-PZQ ODT 50 milligram/Kilogram (mg/Kg) after food-intake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Treatment 1b: Biltricide®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants aged 4 to 6 years infected with S. mansoni will receive single oral dose of Biltricide® 40 mg/Kg crushed tablet after food intake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: L-PZQ ODT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 2 to 3 years infected with S. mansoni will receive single oral dose of L-PZQ ODT 50 mg/Kg after the food intake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: L-PZQ ODT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 3 to less than 24 months infected with S. mansoni will receive single oral dose of L-PZQ ODT 50 mg/Kg after the food intake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: L-PZQ ODT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 3 months to 6 years infected with S. haematobium will receive single oral dose of L-PZQ ODT 50 mg/Kg after the food intake. Additional participants will receive 60 mg/Kg of L-PZQ ODT as decided by the Independent data monitoring committee (IDMC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-PZQ ODT</intervention_name>
    <description>Participants will receive single oral dose of L-PZQ ODT 50 mg/Kg on Day 1.</description>
    <arm_group_label>Cohort 1, Treatment 1a: L-PZQ ODT</arm_group_label>
    <arm_group_label>Cohort 2: L-PZQ ODT</arm_group_label>
    <arm_group_label>Cohort 3: L-PZQ ODT</arm_group_label>
    <arm_group_label>Cohort 4: L-PZQ ODT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biltricide®</intervention_name>
    <description>Participants will receive single oral dose of Biltricide® 40 mg/kg crushed tablet on Day 1.</description>
    <arm_group_label>Cohort 1, Treatment 1b: Biltricide®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-PZQ ODT</intervention_name>
    <description>Participant will receive single oral dose of L-PZQ ODT 60 mg/kg as decided by the IDMC.</description>
    <arm_group_label>Cohort 4: L-PZQ ODT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of the participant is 4 to 6 years of age (Cohorts 1 and 4), 2 to 3 years of age&#xD;
             (Cohorts 2 and 4) 3 to less than 24 months of age (Cohorts 3 and 4)&#xD;
&#xD;
          -  Participants are; Schistosoma (S.) mansoni positive (Cohorts 1, 2, and 3); diagnosis&#xD;
             defined as positive egg counts in stool greater than or equal to ( &gt;=) 1 egg per 1&#xD;
             occasion) according to World Health Organization (WHO) classification [1]: light (1 to&#xD;
             99 eggs per gram of feces), moderate (100 to 399 eggs per gram of feces) and heavy (&gt;=&#xD;
             400 eggs per gram of feces) infections; S. haematobium positive (Cohort 4); diagnosis&#xD;
             defined as positive egg counts in urine (&gt;= 1 egg per 10 milliliter(mL) urine)&#xD;
             according to WHO classification (Prevention and Control of Schistosomiasis and Soil&#xD;
             Transmitted Helminthiasis. WHO Technical Report Series No. 912. WHO, Geneva,&#xD;
             Switzerland, 2002).light (less than (&lt;) 50 eggs per 10 mL of urine) and heavy (&gt;=50&#xD;
             eggs per 10 mL of urine) infections&#xD;
&#xD;
          -  Participants have a minimum body weight of 8.0 Kilograms (Kg) in 2 to 6 years of age&#xD;
             children and 5.0 Kg in 3 months to &lt; 24 months of age infants and toddlers&#xD;
&#xD;
          -  Parent's or guardian/legally authorized representative's ability to communicate well&#xD;
             with the Investigator and his/her delegate, to understand the protocol requirements&#xD;
             and restrictions, and to be willing to have their children comply with the&#xD;
             requirements of the entire study, that is:&#xD;
&#xD;
               -  To be examined by a study physician at screening and 17 to 21 days after&#xD;
                  treatment&#xD;
&#xD;
               -  To provide stool samples at screening and 17 to 21 days after treatment&#xD;
&#xD;
               -  To provide urine samples at screening and 17 to 21 days after treatment&#xD;
&#xD;
               -  To provide venous blood samples for laboratory assessments&#xD;
&#xD;
               -  To be housed in the clinic for 12 to 24 hours&#xD;
&#xD;
               -  To provide venous blood samples for pharmacokinetics (PK) assessments (for&#xD;
                  participants in the PK subset)&#xD;
&#xD;
          -  Participants have a minimum hemoglobin level of 10 gram per deciliter&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with following medical conditions are excluded from the study; Findings&#xD;
             in the clinical examination and/or laboratory safety examination on the treatment day,&#xD;
             that in the opinion of the Investigator constitute a risk or a contraindication for&#xD;
             the child's participation in the study or that could interfere with the study&#xD;
             objectives, conduct or evaluation. This includes but is not restricted to bacterial or&#xD;
             viral infections, such as dysentery, gastroenteritis, ascites, jaundice, etc.;&#xD;
             Participants with seizures and/or medical history of seizures and/or other signs of&#xD;
             potential central nervous system involvement; Participants with known cysticercosis,&#xD;
             or with signs or symptoms (for example: subcutaneous nodules) suggestive of&#xD;
             cysticercosis; Participants with an acute infection or other acute illness within the&#xD;
             7 days prior to study screening; Debilitating illness such as tuberculosis,&#xD;
             malnutrition, etc.&#xD;
&#xD;
          -  Treatment with PZQ within the 4 weeks prior to the study screening&#xD;
&#xD;
          -  Concomitant treatment (within 2 weeks prior to enrollment) with medication that might&#xD;
             affect the metabolism of PZQ, such as certain anti epileptics (for example:&#xD;
             carbamazepine or phenytoin), glucocorticosteroids (for example: dexamethasone),&#xD;
             chloroquine, rifampicin or cimetidine (see Biltricide® Summary of Product&#xD;
             Characteristics [SmPC])&#xD;
&#xD;
          -  Treatment within the 2 weeks prior to the study screening with anti malarial&#xD;
             medications&#xD;
&#xD;
          -  For infants and toddlers being breast fed, treatment of the mothers/wet nurses with&#xD;
             PZQ in the 3 days prior to PZQ ODT administration&#xD;
&#xD;
          -  Participation in any clinical study within 4 weeks prior to administration of PZQ ODT,&#xD;
             or anticipated at any time until completion of the End of study visit&#xD;
&#xD;
          -  Participants with marked increases of the liver enzymes: alanine aminotransferase&#xD;
             and/or aspartate aminotransferase above 3 times the upper limit of normal (ULN); total&#xD;
             bilirubin level above 1.5 times the ULN&#xD;
&#xD;
          -  Participants with hepatosplenic schistosomiasis&#xD;
&#xD;
          -  Fever, defined as temperature above 37.5 degree Celsius axillary or oral mixed S.&#xD;
             haematobium and S. mansoni infections&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitè de Cocody</name>
      <address>
        <city>Abidjan</city>
        <zip>22BP770</zip>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kemri Kisumu</name>
      <address>
        <city>Kisumu</city>
        <zip>40100</zip>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Côte D'Ivoire</country>
    <country>Kenya</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS200661_0003</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 15, 2019</study_first_submitted>
  <study_first_submitted_qc>February 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schistosomiasis</keyword>
  <keyword>Children</keyword>
  <keyword>L-praziquantel</keyword>
  <keyword>Biltricide®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schistosomiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Praziquantel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Within six months after the approval of a new product or a new indication for an approved product in both the United States and the European Union</ipd_time_frame>
    <ipd_access_criteria>Qualified scientific and medical researchers can request the data. Such requests must be submitted in writing to the company's portal and will be internally reviewed regarding criteria for researchers' qualification and legitimacy of the research proposal.</ipd_access_criteria>
    <ipd_url>http://bit.ly/IPD21</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

